Peter Salzmann Sells 16,163 Shares of Immunovant, Inc. (NASDAQ:IMVT) Stock

Immunovant, Inc. (NASDAQ:IMVT) CEO Peter Salzmann sold 16,163 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $29.65, for a total transaction of $479,232.95. Following the sale, the chief executive officer now directly owns 1,036,716 shares in the company, valued at approximately $30,738,629.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Peter Salzmann also recently made the following trade(s):

• On Wednesday, April 17th, Peter Salzmann sold 34,079 shares of Immunovant stock. The stock was sold at an average price of $29.06, for a total transaction of $990,335.74.
• On Tuesday, April 9th, Peter Salzmann sold 4,807 shares of Immunovant stock. The stock was sold at an average price of $31.18, for a total transaction of $149,882.26.

Immunovant Stock Performance

NASDAQ:IMVT traded up $0.56 during trading hours on Friday, reaching $28.95. 739,078 shares of the company were exchanged, compared to its average volume of 1,145,916. The stock’s 50-day moving average is $30.12 and its 200-day moving average is $35.07. Immunovant, Inc. has a twelve month low of $18.16 and a twelve month high of $45.58.

Institutional Investors Weigh In On Immunovant

A number of hedge funds have recently modified their holdings of the business. Castleark Management LLC acquired a new stake in shares of Immunovant in the first quarter valued at about $2,599,000. Bamco Inc. NY grew its holdings in shares of Immunovant by 1.7% in the first quarter. Bamco Inc. NY now owns 60,000 shares of the company’s stock valued at $1,939,000 after purchasing an additional 1,000 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Immunovant by 16.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,862,043 shares of the company’s stock valued at $60,163,000 after purchasing an additional 259,481 shares during the period. Tyro Capital Management LLC grew its holdings in shares of Immunovant by 117.0% in the first quarter. Tyro Capital Management LLC now owns 97,667 shares of the company’s stock valued at $3,156,000 after purchasing an additional 52,667 shares during the period. Finally, Alpine Global Management LLC grew its holdings in shares of Immunovant by 34.6% in the first quarter. Alpine Global Management LLC now owns 1,882,704 shares of the company’s stock valued at $60,830,000 after purchasing an additional 484,332 shares during the period. 47.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IMVT has been the topic of several research analyst reports. Oppenheimer started coverage on shares of Immunovant in a research report on Thursday, March 28th. They set an “outperform” rating and a $50.00 target price on the stock. Truist Financial reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Immunovant in a report on Monday, March 25th. The Goldman Sachs Group started coverage on shares of Immunovant in a report on Wednesday, March 13th. They issued a “buy” rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. started coverage on shares of Immunovant in a report on Tuesday, February 20th. They issued an “overweight” rating and a $51.00 price objective on the stock. Finally, Wolfe Research started coverage on shares of Immunovant in a report on Thursday, February 15th. They issued an “outperform” rating and a $55.00 price objective on the stock. Seventeen analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $49.00.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.